Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
    1.
    发明申请
    Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram 审中-公开
    使用西酞普兰的对映体富集的脱甲基和二甲基 - 代谢物治疗抑郁症和其他CNS障碍的方法

    公开(公告)号:US20040266864A1

    公开(公告)日:2004-12-30

    申请号:US10842055

    申请日:2004-05-07

    Applicant: Sepracor Inc.

    CPC classification number: C07D307/87 C07D317/20

    Abstract: This invention relates to novel compositions of matter containing enantiomerically enriched (null)-desmethylcitalopram, (null)-didesmethylcitalopram, or (null)-didesmethylcitalopram or mixtures thereof in optimal ratios. Contrary to prior teachings, the enantiomerically enriched citalopram metabolites disclosed herein possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine (NE) or dopamine (DA). The present invention also discloses methods for treating disorders, dysfunctions and diseases for which inhibition of serotonin reuptake is therapeutically beneficial. In particular, the present invention discloses a method for treating various forms of depression with pharmaceutical compositions described herein.

    Abstract translation: 本发明涉及以最佳比例含有对映体富集( - ) - 去甲基西酞普兰,(+) - 二甲基西酞普兰或( - ) - 二甲基西酞普兰或其混合物的物质的新型组合物。 与现有技术相反,本文公开的对映异构体富集的西酞普兰代谢物具有有效的5-羟色胺再摄取抑制活性,对其他已知的单胺例如去甲肾上腺素(NE)或多巴胺(DA)的再摄取具有最小的抑制作用。 本发明还公开了治疗疾病,功能障碍和5-羟色胺再摄取抑制治疗有益的疾病的方法。 特别地,本发明公开了一种用本文所述的药物组合物治疗各种形式的抑郁症的方法。

Patent Agency Ranking